Anticancer drug therapy for patients with renal dysfunction

Anticancer drug therapy for cancer is developing rapidly, including molecular-targeted drugs and immune checkpoint inhibitors that are used in clinical settings in addition to conventional cytotoxic drugs. In daily clinical practice, clinicians sometimes encounter situations in which the effects of...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2023-05, Vol.28 (5), p.637-643
Main Authors: Suyama, Koichi, Miura, Yuji
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antineoplastic drugs
Antitumor agents
Breath tests
Cancer
Cancer Research
Chemotherapy
Clinical medicine
Clinical trials
Creatinine
Cytotoxicity
Dialysis
Drug dosages
Drug therapy
Humans
Immune checkpoint inhibitors
Immunosuppressive agents
Invited Review Article
Kidney Diseases - chemically induced
Kidney Diseases - drug therapy
Kidneys
Kinases
Liver diseases
Medicine
Medicine & Public Health
Metabolism
Metabolites
Neoplasms - drug therapy
Oncology
Renal Dialysis
Renal function
Risk groups
Surgical Oncology
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticancer drug therapy for cancer is developing rapidly, including molecular-targeted drugs and immune checkpoint inhibitors that are used in clinical settings in addition to conventional cytotoxic drugs. In daily clinical practice, clinicians sometimes encounter situations in which the effects of these chemotherapeutic agents are considered unacceptable in high-risk patients with liver or renal dysfunction, those undergoing dialysis and older adults. There is no clear evidence regarding anticancer drugs administration to patients with renal dysfunction. However, there are indications for dose setting based on the theory of the renal function responsible for drug excretion and past administration experience. This review outlines anticancer drugs’ administration in patients with renal dysfunction.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-023-02315-z